Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting
- Supplementary File 1:
PDF-Document (PDF, 680 KiB)
Euesden, J.; Gowrisankar, S.; Qu, A.X.; St. Jean, P.; Hughes, A.R.; Pulford, D.J. Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. Genes 2020, 11, 501. https://doi.org/10.3390/genes11050501
Euesden J, Gowrisankar S, Qu AX, St. Jean P, Hughes AR, Pulford DJ. Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. Genes. 2020; 11(5):501. https://doi.org/10.3390/genes11050501
Chicago/Turabian StyleEuesden, Jack, Sivakumar Gowrisankar, Angela X. Qu, Pamela St. Jean, Arlene R. Hughes, and David J. Pulford. 2020. "Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting" Genes 11, no. 5: 501. https://doi.org/10.3390/genes11050501


